BioSpace News Archive

ECMOHO Limited today announced a change in its board of directors (the “Board”).

Biohaven Pharmaceutical Holding Company Ltd. today announced that the Board of Directors unanimously elected Vlad Coric, MD to the role of Chairman of the Board of Directors following the retirement of Declan Doogan, MD, effective immediately.

Antios Therapeutics, Inc. today announced two oral presentations will be presented at the Hep DART 2021 meeting being held December 5-9, 2021, in Cabo San Lucas, Mexico.

Biohaven today announced positive topline results from the second pivotal clinical trial (NCT04571060) evaluating the safety and efficacy of its investigational therapy, intranasal zavegepant, for the acute treatment of migraine in adults.

Enveric Biosciences today announced the appointment of Bob Dagher , MD, as Chief Medical Officer.

Inflammasome Therapeutics (https://inflam.com), said today that research published in Science Immunology (https://www.science.org/doi/10.1126/sciimmunol.abi4493) “DDX17 is an essential mediator of sterile NLRC4 inflammasome activation by retrotransposon RNAs”, uncovers a previously unrecognized mechanism by which NLRC4 combines with NLRP3 to form activated inflammasomes that trigger causes of active disease in macular degeneration and lupus.

Recursion (NASDAQ: RXRX), a clinical-stage biotechnology company decoding biology to radically improve lives by industrializing drug discovery, development and beyond through disruptive innovation, today announced expansion of the company’s existing strategic collaboration in fibrosis with Bayer AG.

Axcella Therapeutics today announced that Margaret Koziel, M.D., has been promoted to the role of Chief Medical Officer and added as a member of the company’s executive team.

RedHill Biopharma Ltd. today announced that because opaganib’s [1] proposed mechanism of action is not impacted by spike protein mutations, opaganib is expected to be unaffected by mutations associated with Omicron and other known variants of concern.

IO Biotech announced today that it has entered into a third clinical trial collaboration and supply agreement with Merck & Co., Inc., Kenilworth, NJ, USA (known as MSD outside the US and Canada), through a subsidiary.